Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders & Insider Trades
Alnylam Pharmaceuticals shareholders at a glance
The largest holder of Alnylam Pharmaceuticals stock is Fidelity Management & Research Co. LLC, with 15.0 million shares (11.23% of the company), worth about $3.62 billion as of September 25, 2026. The 10 largest holders together own 54.5%.
In Q2 2026, 839 institutional holdings reports listed shares worth $42.60 billion.
Insiders reported 99 transactions in the last two years: 43 sales worth $111.89 million and no purchases. The newest one on file is from May 13, 2026 (Schulman Amy W., Director).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 13, 2026.
Alnylam Pharmaceuticals, Inc.
Shareholders Summary
2026Q2
Ownership by Type
Geographic Distribution
Largest Alnylam Pharmaceuticals shareholders
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Fidelity Management & Research Co. LLC | 15.0 million | 11.23% | $3.6B |
| Capital Research & Management Co. (World Investors) | 11.1 million | 8.33% | $2.7B |
| Capital Research & Management Co. (Global Investors) | 9.8 million | 7.29% | $2.3B |
| BlackRock Advisors LLC | 8.8 million | 6.55% | $2.1B |
| Vanguard Portfolio Management LLC | 6.5 million | 4.89% | $1.6B |
| Vanguard Capital Management LLC | 6.0 million | 4.51% | $1.5B |
| T. Rowe Price Investment Management, Inc. | 5.6 million | 4.22% | $1.4B |
| Invesco Advisers, Inc. | 3.8 million | 2.81% | $904.0M |
| State Street Corporation | 3.6 million | 2.66% | $856.0M |
| JPMorgan Investment Management, Inc. | 2.7 million | 2.00% | $644.0M |
As of September 25, 2026.
Alnylam Pharmaceuticals institutional holdings by quarter
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 839 | – | $42.6B |
| Q1 2026 | 833 | 131.0 million | $43.4B |
| Q4 2025 | 908 | 134.0 million | $53.2B |
| Q3 2025 | 879 | 138.0 million | $61.3B |
| Q2 2025 | 704 | 134.0 million | $43.3B |
| Q1 2025 | 690 | 131.0 million | $34.9B |
| Q4 2024 | 645 | 129.0 million | $30.1B |
| Q3 2024 | 623 | 128.0 million | $34.7B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
Alnylam Pharmaceuticals insider trades
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Schulman Amy W. | May 13, 2026 | Director | Conversion of Exercise of derivative security at price 70.20 per share. | $789,750 |
| Mclaughlin Melissa | Apr 6, 2026 | Officer | Sale at price 316.61 - 333.94 per share. | $1.3M |
| Garg Pushkal | Mar 5, 2026 | Officer | Sale at price 319.03 - 326.08 per share. | $1.5M |
| Fitzgerald Kevin Joseph | Mar 5, 2026 | Officer | Sale at price 319.03 - 326.24 per share. | $417,685 |
| Tanguler Tolga | Mar 4, 2026 | Officer | Sale at price 319.03 - 325.67 per share. | $745,984 |
| Poulton Jeffrey V | Mar 4, 2026 | Chief Financial Officer | Sale at price 319.03 - 325.67 per share. | $797,351 |
| Greenstreet Yvonne L | Mar 4, 2026 | Chief Executive Officer | Sale at price 319.03 - 325.67 per share. | $947,581 |
| Garg Pushkal | Mar 3, 2026 | Officer | Sale at price 316.74 - 332.64 per share. | $1.1M |
| Fitzgerald Kevin Joseph | Mar 3, 2026 | Officer | Sale at price 316.55 - 332.64 per share. | $1.1M |
| Greenstreet Yvonne L | Mar 2, 2026 | Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Supran Bryan | Mar 2, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Fitzgerald Kevin Joseph | Mar 2, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
Newest 12 of 99 insider transactions in the last two years.
Questions and answers
Who owns the most Alnylam Pharmaceuticals stock?
Fidelity Management & Research Co. LLC, with 11.23% of the company (as of September 25, 2026). Next: Capital Research & Management Co. (World Investors) (8.33%) and Capital Research & Management Co. (Global Investors) (7.29%).
How many institutions own Alnylam Pharmaceuticals stock?
839 institutional holdings reports listed Alnylam Pharmaceuticals shares in Q2 2026 worth $42.60 billion.
Are Alnylam Pharmaceuticals insiders buying or selling the stock?
In the last two years insiders reported 43 sales and no purchases (99 transactions in all); the newest on file is from May 13, 2026.
